figshare
Browse
1/1
2 files

A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy

dataset
posted on 2017-10-14, 10:13 authored by Arthur Jochems, Issam El-Naqa, Marc Kessler, Charles S. Mayo, Shruti Jolly, Martha Matuszak, Corinne Faivre-Finn, Gareth Price, Lois Holloway, Shalini Vinod, Matthew Field, Mohamed Samir Barakat, David Thwaites, Dirk de Ruysscher, Andre Dekker, Philippe Lambin

Background: Early death after a treatment can be seen as a therapeutic failure. Accurate prediction of patients at risk for early mortality is crucial to avoid unnecessary harm and reducing costs. The goal of our work is two-fold: first, to evaluate the performance of a previously published model for early death in our cohorts. Second, to develop a prognostic model for early death prediction following radiotherapy.

Material and methods: Patients with NSCLC treated with chemoradiotherapy or radiotherapy alone were included in this study. Four different cohorts from different countries were available for this work (N = 1540). The previous model used age, gender, performance status, tumor stage, income deprivation, no previous treatment given (yes/no) and body mass index to make predictions. A random forest model was developed by learning on the Maastro cohort (N = 698). The new model used performance status, age, gender, T and N stage, total tumor volume (cc), total tumor dose (Gy) and chemotherapy timing (none, sequential, concurrent) to make predictions. Death within 4 months of receiving the first radiotherapy fraction was used as the outcome.

Results: Early death rates ranged from 6 to 11% within the four cohorts. The previous model performed with AUC values ranging from 0.54 to 0.64 on the validation cohorts. Our newly developed model had improved AUC values ranging from 0.62 to 0.71 on the validation cohorts.

Conclusions: Using advanced machine learning methods and informative variables, prognostic models for early mortality can be developed. Development of accurate prognostic tools for early mortality is important to inform patients about treatment options and optimize care.

Funding

This work was supported by the Interreg grant euroCAT and the Dutch Technology Foundation STW [DuCAT, grant no. 10696; Radiomics STRaTegy, grant no. P14-19], which is the applied science division of Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO); the Technology Programme of the Ministry of Economic Affairs; and the Cancer Research UK Manchester Centre grants (C147/A18083) and (C147/A25254). The authors also acknowledge financial support from the EU 7th framework program [ARTFORCE, grant no. 257144, REQUITE, grant no. 601826], CTMM-TraIT, EUROSTARS (CloudAtlas), Kankeronderzoekfonds Limburg from the Health Foundation Limburg, Alpe d’HuZes-KWF (DESIGN), The Dutch Cancer Society, NIH P01 CA059827, the European Program H2020-2015-17 [ImmunoSABR, grant no. 733008], the ERC advanced grant [ERC-ADG-2015, grant no. 694812; Hypoximmuno], SME Phase 2 (EU proposal 673780, RAIL).

History